Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.

NCT05945823 is registered in ClinicalTrials.gov with Taiho Oncology, Inc. as lead sponsor.

NCT NCT05945823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05945823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
Lead sponsor
Taiho Oncology, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 13, 2023
Completion date
January 31, 2027
Enrollment
53 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, esophageal squamous cell cancer, locally advanced unresectable or metastatic solid tumors including esophageal cancer, pancreatic cancer, siewert type 1 gej cancer